Opening Comments at the American Association for the Advancement of Science (AAAS) consultation on Human Enhancement
By Richard Hayes
| 06. 01. 2006
Mark Frankel asked if we’d share some general perspectives on what we believe to be the major challenges posed as we consider technologies of “enhancement.” I’d like to share the perspective of the Center for Genetics and Society, as well as what we’ve learned about the perspectives of a wide range of Americans and others.
CGS got started following a series of meetings held in 2000 on the social and political implications of the new human genetic technologies. The meetings brought together people concerned about social and economic justice, women’s health and reproductive rights, science and society, environmental protection, and the rights of the disabled.
Those participating became concerned when they learned how rapidly these new technologies were being developed, how profoundly consequential these could be, how thin were the few rules and regulations in place, and how well below the radar screens of both the general public and policy makers all this was.
A major concern was that use of these technologies could greatly exacerbate human inequality, in particular through a revival of eugenic technologies and ideologies, this time...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...